Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

treosulfan

View Patient Information
The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:dihydroxybusulfan
treosulphan
tresulfon
US brand name:Grafapex
Foreign brand name:Ovastat
Trecondi
Chemical structure:(S-(R*,R*))-1,2,3,4-butanetetrol,1,4-dimethanesulfonate
L-threitol 1,4-dimethanesulfonate
NSC code:39069
39070
94160
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search